Ceftaroline: new possibilities of shortterm courses of antibacterial therapy in hospitalized patients with extramural pneumonia
The data on the effectiveness of new cephalosporin, ceftaroline, for the treatment of patients with extramural pneumonia in need of hospitalization. They show that the use of ceftaroline for 5-7 days for the treatment of hospitalized patients with extramural pneumococcal pneumonia exceeding standard therapy with ceftriaxone in terms of efficacy. Therapeutic effect of ceftaroline did not depend on S.pneumoniae serotype and persisted in severe cases complicated by bacteriemia. Another advantage of ceftaroline over ceftriaxone is it ensured an adequate response on day 4 of therapy. Evidently, properly designed prospective studies are needed to better understand the role of ceftaroline in the treatment of hospitalized patients with extramural pneumonia, estimate cost and effect ratio, and elucidate the frequency and character of adverse reactions related to the long stay of the patient in a clinic.